Kornimate/medical-research-clean huggingface dataset:
medical management survey : organization of perioperative practices in anesthesia and ambulatory surgery

Conditions: Surgery

Summary: in france, there are no precise data regarding perioperative organization of medical structure and care management of ambulatory surgical patients. particularly, data on management of pain, nausea and vomiting, as well as venous thromboembolic, prevention and treatment are needed, in several groups of patients.

this is a prospective epidemiological observationnal study involving a sample of 300 ambulatory surgical centers among 1000 french centers. in a first step, a survey on the specific organization and care management of the structure will be carried out. in a second step, data on the management of 3000 patients admitted in these structure will be performed. the will allow an analysis of practices in a selection of acts (which seem to be more frequent and more relevant). data from three different questionnaires on pain management, ponv prevention and treatment and vte prevention will be recorded for each patient.

Eligibility criteria:
inclusion criteria: * all patients managed for ambulatory surgery by medical structures during the two days of the survey. * for the patient managed for specific ambulatory surgery by medical structures, a more detail survey will be conducted (if applicable). specific surgery are :oral surgery ( wisdom tooth extraction surgery), knee arthroscopy, abdominal wall surgery (including inguinal hernia surgery), perianal surgery, varicose veins surgery, cholecystectomy/laparoscopy surgery, lumpectomy, uterine surgery, hallux valgus, hand surgery (except carpal tunnel surgery) exclusion criteria: none

Keywords: ambulatory surgery pain management nausea and vomiting management questionnaire survey management
geriatric assessment at discharge from the intensive care unit in patients aged 75 years and older: a feasibility study

Conditions: Critical Illness; Geriatric Assessment; Older People; Frailty

Summary: the number of patients aged over 75 continues to grow, and, according to insee, will represent almost 10% of the french population in 2021, an increase of 2.4 points since 2000. this demographic change is also observed in the intensive care units, where admitted patients aged over 80 represent now up to 10-20% of critical care admissions, depending on the facility. the admission of these patients remains controversial, with questions about the benefit to elderly patients, both in terms of in-hospital and distant survival, as well as induced morbidity or subsequent quality of life: functional status is impaired in up to two-thirds of survivors. the challenge of identifying the patients most able to withstand a stay is a major one. indeed, a stay in intensive care represents a major stress for the organism, due to the acute condition associated with one or more organ failure(s). bed rest, immobilization and the use of drugs are responsible for formidable complications in the elderly: muscle-wasting, loss of adaptation to physical effort, loss of autonomy, delirium and agitation, all of which have their own long-term impact. while many studies have looked at the prognostic factors on admission of these patients, and the selection of the patient with the greatest probability of surviving the intensive care unit (icu), improving the outcome of patients who survive to the icu stay remains a little-investigated subject. however, the impact of physical and psychological disturbances induced by these patients' stay in intensive care is major, and their detection and management could be elements of interest in improving the care of this population. however, the feasibility of carrying out such an assessment immediately after an icu stay has yet to be evaluated. the aim of this study would be to evaluate the feasibility of a geriatric assessment at the end of the icu stay (or within 7 days of discharge) and at 6 months. this study is a prospective, randomized, single-center, open-label interventional study.


Eligibility criteria:
inclusion criteria: * patients over 75 years of age * admitted to the intensive care unit, for whatever reason, and having survived their stay, considered as leaving the intensive care unit. * subjects affiliated to a health insurance scheme * able to understand the aims and risks of the research and to give dated, signed informed consent, * in the event of confusion on leaving the intensive care unit, a close relative available to give dated, signed informed consent, with the patient's consent collected as soon as his or her condition permits. exclusion criteria: * protected subject as defined by law: safeguard of justice, guardianship or curatorship procedures * subject moribund, or whose life expectancy as estimated by the clinician in charge is less than 1 month * patient not living in bas-rhin (visit to m6)
contact force sensing use in atrial fibrillation ablation

Conditions: Atrial Fibrillation

Summary: there are multiple important factors which need to be monitored when conducting ablation for atrial fibrillation. the contact between the catheter tip and the inside of the heart wall is now measurable and may improve the effectiveness of catheter ablation for atrial fibrillation patients.

this study compares patients who have this procedure where this contact information is known (unblinded) versus those where the contact information is not known (blinded). the outcome is the rate of acute reconnection at 1 hour after achieving pulmonary vein isolation.

Eligibility criteria:
inclusion criteria: * patients with symptomatic af exclusion criteria: * recent cva * contraindication to warfarin therapy
the effects of sedatives on tobacco use disorder version 2

Conditions: Tobacco Smoking

Summary: double-blind, placebo-controlled, randomized mechanistic clinical trial to test an intravenous dose of either ketamine, midazolam, dexmedetomidine, or a placebo (saline) on cigarette smoking behavior, craving, and neural effects.

this double-blind, placebo-controlled, randomized mechanistic clinical trial will test non-treatment seeking smokers with an intravenous infusion of ketamine (0.71 mg/kg), midazolam (0.025 mg/kg), dexmedetomidine (0.025 mg/kg), or placebo, at least 2 weeks apart. participants will complete 7-day ecological momentary assessment (ema) of daily craving, withdrawal, and smoking behavior before and after each infusion. they will be asked to abstain from tobacco/nicotine for twenty-four hours post-infusion to induce withdrawal symptoms and return to the lab the following day to complete measures of craving, withdrawal, an mri scan, and smoking latency. after this study visit, participants will be allowed to smoke as usual for the rest of the ema diary period. physical and subjective effects and adverse effects will be closely monitored throughout.

Eligibility criteria:
inclusion criteria: * smokes cigarettes daily for at least 2 years * afternoon expired breath carbon monoxide at least 5 ppm or morning urinary cotinine at least 100 ng/ml * negative urine drug screen for psychoactive drugs and negative breath alcohol exclusion criteria: * have an unstable medical condition or stable medical condition that would interact with study drug or participation, including chronic pulmonary disease, coronary artery disease, current brain tumor, current increased intracranial pressure or impaired consciousness * history of serious head trauma or neurological disorder (e.g., seizure disorder) * have any of the following: hypertension (i.e., systolic \>140 mm hg and/or diastolic \>90 mm hg on three separate measures; systolic \>170 or diastolic \> 110 on any occasion), pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic). * use of drugs that would interact with study drug or increase risk of adverse events * among women, pregnancy or lactation

Keywords: nicotine addiction smoking placebo sedatives
role of macrophage migratory inhibitory factor in systemic sclerosis

Conditions: System; Sclerosis

Summary: migration inhibitory factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in disease-affected tissues

* systemic sclerosis (scleroderma) is a disease of unknown etiology characterized by fibrosis of the skin and internal organs, pronounced vasculopathy, and dysregulated immune system. * clinically, the disease is divided into 2 major subsets, diffuse cutaneous ssc (dcssc) and limited cutaneous ssc (lcssc). the diffuse cutaneous subtype is generally associated with significant internal organ involvement, especially renal crisis and diffuse alveolitis of the lung, along with antitopoisomerase (antitopo) autoantibody. the limited cutaneous subtype is distinguished by raynaud's phenomenon, telangiectasias, pulmonary hypertension, and the presence of anticentromere antibody. however, there is significant overlap both in the clinical manifestations and in the specific autoantibodies that occur in these subtypes. it is not known what predisposes a susceptible individual to develop one subtype versus another, nor is there significant information about how the 2 disease subtypes may be pathogenically related. * activation of t lymphocytes and macrophages is an early event in the parthenogenesis of ssc. activated t cells , macrophages and endothelial cells are important sources of macrophage migration inhibitory factor mif was initially identified as the protein secreted by activated t lymphocytes capable of inhibiting random migration of macrophages, concentrating macrophages at inflammation loci, and enhancing their ability to kill intracellular parasites and tumoral cells. * migration inhibitory factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in disease-affected tissues. * in patients with ssc, elevated serum levels of mif, increased mif expression in the skin and afunctional promoter polymorphism in the mif gene that might influence clinical expression have been described therefore mif might have an important role in the disease.

Eligibility criteria:
inclusion criteria: -patients with systemic sclerosis . exclusion criteria: * patients with interstitial pulmonary fibrosis caused by causes other than ssc. * other rheumatologic diseases. * overlap or mixed diseases. * patients with renal disease caused by causes other than ssc. * unwillingness to participate in the study.
role of exosomes in pancreatic cancer progression

Conditions: Pancreatic Cancer

Summary: the present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their potential use as predictive and diagnostic markers for this tumor of difficult early diagnosis and often inauspicious prognosis.

the study is cross-sectional, single-center, spontaneous, in human tissues. it is a pilot study to gather evidence on the content of extracellular vesicles/exosomes in patients with pancreatic cancer. the study will be performed on tumor tissue, blood and urine samples. tissue will be obtained by needle biopsy (fine needle biopsy - fnb) during echoendoscopic examination. the study aims to characterize the content of extracellular vesicles/exosomes in the biological fluids of subjects with pancreatic cancer with the goal of identifying new markers for this disease. to this end, the following will be carried out: * an ex vivo and in vitro characterization study of the secretion of these extracellular vesicles/exosomes with analysis of their contents in terms of proteins and nucleic acids; * a study of the mechanisms of epithelial-mesenchymal transition (emt), invasion and aggressiveness to highlight a possible association between the secretion of these vesicles and the oncological stage of pancreatic carcinoma;

Eligibility criteria:
inclusion criteria: * people with pancreatic cancer * 18 years old * obtaining informed consent. exclusion criteria: * patients who do not need or cannot perform endoscopy with biopsy sampling; * patients with a previous or active neoplastic pathology, different from pancreatic neoplasia.
the effects of specialized footwear in osteoarthritis

Conditions: Knee Osteoarthritis

Summary: this study evaluates the effects of specialized footwear on pain and knee loading in knee osteoarthritis. the hypothesis is that this footwear will lead to decreased knee loading and knee pain.


Eligibility criteria:
inclusion criteria: * able and willing to give informed consent and to comply with the study protocol and follow-up instructions. * symptomatic oa of the knee, as defined by the american college of rheumatology's clinical criteria for classification and reporting of oa of the knee. if symptoms are bilateral, then the knee identified by the subject as more symptomatic will serve as the index knee. * ambulatory knee pain, defined as the presence of greater than 30 mm of pain while walking on a flat surface (corresponding to question 1 of the visual analog format of the womac. * radiographic oa of the study knee of grade 2 or 3, as defined by the modified kellgren and lawrence (k-l) grading scale. * medial compartment oa, defined as either qualitative joint space narrowing of ≥ 1or the presence of medial bone cyst, sclerosis, or osteophyte. exclusion criteria: * inability or unwillingness to wear study shoes for at least 6 hours/day for 6 days/week * knee flexion contracture of \> 15 degrees or inability to ambulate without assistance. * presence of clinically significant oa of the hip or ankle or pain greater than 20 mm at these sites (womac). * \> 3 degrees valgus or \>12 degrees varus deformity of either knee, defined by the mechanical axis (hip-knee angle). * predominant lateral compartment oa, defined as narrowing of the lateral joint space in excess of the narrowing of the medial joint space in either the index or the contralateral knee. * concurrent systemic inflammatory arthropathy, * prior knee or hip arthroplasty, or surgical arthroscopy of either knee within previous 3 months or history of fracture of either lower extremity within 6 months of study entry. * intrinsic foot disease including hallux rigidus, hallux abducto-valgus, metatarsalgia, plantar fasciitis, peripheral neuropathy, or any foot condition that may be exacerbated by particular footwear. * intra-articular injection in the index knee: steroids within 6 weeks, hyaluronan derivatives within 4 months. * pregnant subjects will be excluded because of the x-rays required. * any medical condition that, in the opinion of the pi, would render the subject unable to complete the study.

Keywords: knee osteoarthritis loading
iterative picc placement versus long term device

Conditions: Breast Cancer

Summary: peripherally inserted central catheter (picc) and port-a-cath (pac) are the most commonly medical devices used for the administration of chemotherapy. placement of these devices via central venous access is sometimes responsible for complications. the incidence of these complications is correlated with the device holding time. a strategy of iterative picc placement could significantly reduce these complications.


Eligibility criteria:
inclusion criteria: * women older than 18 years old; * breast cancer diagnosis histologically proven , for any histological subtypes; * 4 or 6 indication of neoadjuvant or adjuvant chemotherapy; according to hormonal status and her2 of the tumors, the patient may be treated concomitantly with hormone therapy and / or trastuzumab; nota bene: treatment protocol adopted will imperatively be administered in 3-week cycles. * central venous access indication; * ability to understand and willingness to comply with the study monitoring; * affiliated to the french social security system; * informed consent dated and signed, indicating that the patient has been informed of all pertinent aspects of the study before inclusion. exclusion criteria: * any contraindication for placement of a central venous catheter ( hemostasis disorders , active infection treated with antibiotics , ...); * patient who can't stop anti -vitamin k treatment ( avk ) ( a relay by heparin low molecular weight (lmwh) is possible); * history of central access, regardless of the indication; * any active disease other than cancer pathology , requiring repeated administration of intravenous therapy ; * patient deprived of liberty; * not monitoring for social, geographical, psychological or family reason.

Keywords: breast cancer chemotherapy peripherally inserted central catheter implantable device randomized controlled trial iterative placement catheterization, central venous
amla on metabolic syndrome, insulin sensitivity and insulin secretion

Conditions: Metabolic Syndrome

Summary: amla has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. the above mentioned findings show that amla has an excellent potential for the prevention and treatment of metabolic syndrome.

a randomized, double-blind, placebo-controlled clinical trial will be conducted in 28 patients, 30-59 years old, with diagnosis of metabolic syndrome according with modified international diabetes federation criteria. patients will be randomly assigned to receive amla (500mg) or homologated placebo orally twice daily, for 90 days. before and after the intervention, the components of metabolic syndrome will be evaluated, waist circumference, blood pressure, levels of fasting glucose, triglycerides, cholesterol high density lipoprotein (c-hdl), total insulin secretion (insulinogenic index), first phase of insulin secretion (stumvoll index) and insulin sensitivity (matsuda index).

Eligibility criteria:
inclusion criteria: * diagnosed metabolic syndrome according to the idf criteria: * - - waist circumference: ≥80 cm (women) ≥90 cm (men), plus two or more of the following: * - - fasting glucose ≥ 100 mg/dl to \<126 mg/dl. * - - triglycerides ≥150 mg/dl to \<499 mg/dl * - - hdl-c: men ≤40 mg/dl, women ≤50 mg/dl * - - systolic blood pressure ≥130 to \<140 mmhg * - - diastolic blood pressure ≥85 to \<89 mmhg * body mass index between 25 and 34.9 kg/m² * no pharmacological treatment for metabolic syndrome exclusion criteria: * pregnancy or breast-feeding * known allergy to amla or placebo * history of hepatic, kidney or thyroid disease * drugs or supplements consumption with proven properties that modify the behavior of the metabolic syndrome

Keywords: amla emblica officinalis metabolic syndrome insulin secretion insulin sensitivity
a study to determine the excretion balance, pharmacokinetics, metabolism and absolute oral bioavailability of a single oral dose of [14c]-labeled idasanutlin and an intravenous tracer dose of [13c]-labeled idasanutlin in a single cohort of participants with solid tumors (malignancies)

Conditions: Solid Tumors

Summary: the purpose of this single-center, open-label, non-randomized study is to assess the excretion balance, pharmacokinetics, metabolism and absolute oral bioavailability of \[14c\]-labeled idasanutlin administered orally and \[13c\]-labeled idasanutlin administered intravenously in a single cohort of eligible participants. participants will be screened for participation in this study within 21 days of receiving the first dose of study drug on day 1. treatment period will continue up to day 28 after which participants will enter 28 day follow-up or the optional treatment extension of idasanutlin, depending on safety parameters and as per opinion of the investigator.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 to 2, at the discretion of the investigator * histologically or cytologically confirmed advanced malignancy, except leukemia and lymphoma * measureable or evaluable disease by response evaluation criteria in solid tumors (recist) version 1.1, with no more than a single active malignancy in the previous 3 to 5 years prior to the administration of study drug * life expectancy of at least 12 weeks * participants taking opioid analgesics for pain should be on a stable pain and palliative care bowel regimen for one month prior to the first dose of study medication * adequate bone marrow, hepatic, and renal function * agreement to remain abstinent or use contraceptive methods specified in the study exclusion criteria: * history of any form of leukemia, except for stage 0 - 1 chronic lymphocytic leukemia, not requiring treatment in addition to their underlying malignancy * have received hormonal therapy within the two weeks prior to the first dose of study drug * have pre-existing gastrointestinal disorders that may interfere with proper absorption of the drug * history of seizure disorders or unstable central nervous system metastases (participants with stable cns metastases allowed) * have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * receive certain per protocol prohibited medications while on study. these medications must be discontinued 7 days prior to start of study drug * have bone marrow disorders, electrolyte imbalance, infrequent bowel movements (less than once per 48 hours), coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia * positive for human immunodeficiency virus currently receiving combination anti-retroviral therapy * regular work with ionizing radiation or radioactive material or treated with radiotherapy within 3 weeks prior to the first dose of study drug * refuse to potentially receive blood products and/or have a hypersensitivity to blood products
neurophysiology of the basal ganglia, thalamus, and cerebellum in patients with movement disorders

Conditions: Movement Disorders

Summary: the research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as parkinson's disease, essential tremor, dystonia, or ataxia). these brain structures are involved in movement disorders. this study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (dbs). recordings are made from the scalp with a noninvasive electrode and/or through the dbs stimulator if the participant has a stimulator model that is able to sense brain activity. these recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.


Eligibility criteria:
inclusion criteria: * patients 18 years of age and above * any patient who has been diagnosed by a movement disorders neurologist with one of the following movement disorders: * parkinson's disease * dystonia * tremor, including essential tremor * cerebellar ataxia * other hyperkinetic movement disorders, such as chorea and tics exclusion criteria: - patients with dementia